Diamedica down after stroke therapy trial put on clinical hold

DiaMedica Therapeutics

07/07/2022 11:12

** Shares of drug developer Diamedica Therapeutics  DMAC.O 
fall ~31% to $1.39 premarket
    ** Co said after market hours on Wednesday that U.S. FDA has
placed clinical hold on a mid-to-late stage study testing co's
experimental stroke therapy, DM199  urn:newsml:reuters.com:*:nFWN2YN0OR
    ** The therapy is intended to treat acute ischemic stroke,
which is caused by blood clots in arteries
    ** Hold initiated following co's pause in patient enrollment
and submission of three reports to FDA related to cases of low
blood pressure occurring shortly after initiation of intravenous
dose of DM199 - DMAC
    ** Up to last close, stock down 45.8%


 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))